Skip to main content
GeneDx Holdings Corp (WGS)
Health Services • Health Care
Stock AI
News & Reports
August 03, 2026 GeneDx Holdings Corp Faces Class Action Lawsuit: Investors Urged to Act GeneDx Holdings Corp is facing a class action lawsuit for allegedly misleading investors about its financial health. With a critical deadline approaching on August 3, 2026, affected shareholders are urged to evaluate their options and consider legal counsel.
August 03, 2026 GeneDx Holdings Corp Reports 2026 Q2 Financial Results: A Mixed Bag of Growth and Challenges GeneDx Holdings Corp reports strong revenue growth and increased test volumes in Q2 2026 but faces significant net losses and operational challenges. The company must improve reimbursement processes and manage costs to achieve sustainable profitability.
July 31, 2026 GeneDx Holdings Corp Faces Class Action Lawsuit Amid Falling Share Prices GeneDx Holdings Corp is involved in a class action lawsuit due to allegations of undisclosed financial information that led to a significant drop in its stock prices. Investors have until August 3, 2026, to file claims. The lawsuit highlights concerns over the company's operational transparency and financial management.
July 23, 2026 GeneDx Holdings Corp Faces Class Action Lawsuit Amid Allegations of Misleading Statements GeneDx Holdings Corp is facing a class action lawsuit due to alleged misrepresentations regarding its acquisition of Fabric and its impact on financial performance. The Rosen Law Firm is leading the charge for affected shareholders, urging action by August 3, 2026.
July 16, 2026 GeneDx Holdings Corp Set to Announce Q2 2026 Financial Results GeneDx Holdings Corp is set to release its Q2 2026 financial results on August 3, 2026. The company will hold a conference call to discuss these results, showcasing its commitment to genomics and innovation in rare disease diagnostics.
July 16, 2026 GeneDx Holdings Corp Faces Class Action Lawsuit: Allegations of Misleading Investors GeneDx Holdings Corp is embroiled in a class action lawsuit alleging the company misled investors about the benefits of its Fabric Genomics acquisition. Following disappointing financial results, the stock plummeted nearly 50%. Shareholders are encouraged to participate in the lawsuit to seek potential recovery of losses.
July 09, 2026 GeneDx Holdings Corp Faces Class Action Lawsuit Following Disappointing Fabric Genomics Acquisition GeneDx Holdings Corp is under fire from investors following a failed acquisition of Fabric Genomics that resulted in a $31.2 million write-down and a nearly 50% drop in stock value. The class action lawsuit alleges misleading statements by company executives regarding the acquisition's potential benefits, leaving many investors seeking recovery options.
June 16, 2026 GeneDx Appoints Mark Gardner as President to Propel Growth in Genomic Medicine GeneDx has announced the appointment of Mark Gardner as President to lead its expansion in genomic medicine. With nearly three decades of experience in the diagnostics sector, Gardner aims to improve operational efficiency and solidify GeneDx's position as a leader in rare disease diagnosis.
June 11, 2026 GeneDx Holdings Corp Faces Class Action Lawsuit Amid Significant Stock Decline GeneDx Holdings Corp. is facing a class action lawsuit after a significant stock decline linked to misleading statements about its acquisition of Fabric Genomics. Investors have until August 3, 2026, to join the lawsuit, which accuses the company of failing to disclose critical operational issues.
June 09, 2026 GeneDx Holdings Corp Faces Securities Lawsuit Following Fabric Genomics Acquisition Fallout GeneDx Holdings Corp is facing a class action lawsuit due to a significant drop in stock prices after the troubled acquisition of Fabric Genomics. The lawsuit alleges misrepresentation of financial outcomes, with investors suffering heavy losses as the company's growth projections were drastically revised downwards.
June 08, 2026 GeneDx Holdings Faces Securities Fraud Class Action Amidst Significant Stock Decline GeneDx Holdings Corp. is facing a securities fraud class action due to undisclosed financial issues that led to a 49.2% decline in stock value. Investors from April 16, 2025, to May 4, 2026, may be eligible to participate in the lawsuit, with a filing deadline of August 3, 2026.
June 05, 2026 GeneDx Holdings Corp Faces Class Action Lawsuit Amid Allegations of Misleading Investors GeneDx Holdings Corp is facing a class action lawsuit alleging it misled investors about the impact of its Fabric acquisition. Shareholders are urged to participate in the legal proceedings, which could lead to significant financial recovery.
June 05, 2026 GeneDx Holdings Corp Faces Securities Fraud Lawsuit: A Deep Dive into the Allegations GeneDx Holdings Corp is embroiled in a securities fraud lawsuit due to misleading financial disclosures. The Schall Law Firm seeks investors affected during the Class Period to join the action before the August 3, 2026 deadline.
June 04, 2026 GeneDx Holdings Corp Faces Class Action Lawsuit Amid Allegations of Misleading Investors GeneDx Holdings Corp is facing a class action lawsuit for allegedly misleading investors about the benefits of its acquisition of Fabric Genomics. Following disappointing financial results and a significant stock drop, affected shareholders may seek compensation. Robbins LLP is leading the lawsuit and encourages investors to consider their options.
June 04, 2026 GeneDx Holdings Corp Faces Securities Class Action Amid Financial Turmoil GeneDx Holdings Corp is facing a class action lawsuit due to allegations of misleading communications and financial mismanagement. Following a significant drop in share value and disappointing revenue forecasts, investors are urged to act before the August 3rd deadline to join the class action.
May 26, 2026 GeneDx Holdings Corp to Showcase Innovations at Goldman Sachs Global Healthcare Conference GeneDx Holdings Corp will present its innovations in rare disease diagnosis at the Goldman Sachs Global Healthcare Conference from June 8-10, 2026. The company's leadership will engage in a fireside chat to discuss their strategic direction, including the use of advanced genomic testing technologies like GeneDx Infinity™, which supports both clinical diagnostics and biopharmaceutical research.
May 07, 2026 GeneDx Holdings Corp Faces Investigation Amidst Disappointing Q1 Results GeneDx Holdings Corp. is experiencing a significant downturn after reporting disappointing Q1 results, leading to a 50% drop in stock prices. The firm is now under investigation for potential securities fraud as investors express concern over its financial stability and operational challenges.
May 06, 2026 GeneDx Holdings Corp Faces Securities Fraud Investigation Following Disappointing Earnings Report GeneDx Holdings Corp is facing a securities fraud investigation after reporting disappointing first-quarter earnings, including a $57.5 million operational loss. The company's stock plunged nearly 50%, prompting investor concerns and calls for legal action from a law firm specializing in securities litigation.
May 06, 2026 GeneDx Holdings Corp Faces Legal Scrutiny Amid Significant Financial Losses GeneDx Holdings Corp is facing a legal investigation following a reported $57.5 million operational loss and a significant stock price decline of 49.2%. The company has downgraded its revenue expectations and is scrutinized for possible securities fraud, raising concerns among investors.
May 05, 2026 GeneDx Holdings Corp Faces Securities Fraud Investigation Following Disappointing Financial Results GeneDx Holdings Corp is facing a securities fraud investigation after reporting a significant financial loss of $57.5 million and a drastic cut in revenue guidance. Following these revelations, the company's stock plummeted by 50%, prompting investors to consider legal actions for potential recovery.
May 04, 2026 GeneDx Holdings Corp Reports Strong Q1 2026 Financial Results, Adjusts Full-Year Outlook GeneDx Holdings Corp. reported a 17% revenue growth in Q1 2026, reaching $102.3 million. The company anticipates increased testing volume and revenue for the year, alongside strategic initiatives aimed at expanding its market leadership.
May 04, 2026 GeneDx Holdings Corp. Reports Q1 2026 Results: Growth Amid Challenges GeneDx Holdings Corp. reported a 17% revenue increase in Q1 2026, driven by higher test volumes. However, the company faces challenges from declining reimbursement rates and rising operational expenses, leading to a significant net loss. Strategic initiatives for innovation and market engagement are underway to navigate these hurdles.
April 13, 2026 GeneDx Holdings Corp Set to Release Q1 2026 Financial Results GeneDx Holdings Corp is set to announce its Q1 2026 financial results on May 4, followed by a conference call for stakeholders. The company continues to lead in genomic medicine with its innovative platforms and extensive rare disease data.
March 11, 2026 GeneDx Holdings Corp Reports Landmark Savings Through Genomic Testing GeneDx's SAVES-Kids Study showcases the economic benefits of genomic testing, revealing an average savings of $80,000 per child. Early testing significantly reduces healthcare costs and hospitalizations for children with epilepsy and developmental disorders, transforming pediatric care.
March 10, 2026 GeneDx Partners with Zevra Therapeutics to Enhance Genetic Testing for Niemann-Pick Disease Type C GeneDx partners with Zevra Therapeutics to launch a no-cost genetic testing program for Niemann-Pick Disease Type C. This initiative aims to improve diagnosis speed and accuracy, leveraging GeneDx's extensive genomic dataset to enhance patient care.
February 25, 2026 GeneDx Holdings Corp to Showcase Innovations at Upcoming Investor Conferences GeneDx Holdings Corp will showcase its genomic innovations at two key investor conferences in March. With a focus on transparency, the company aims to highlight advancements in rare disease diagnosis and genomic data applications.
February 23, 2026 GeneDx Reports Strong Financial Performance for 2025 and Outlines Ambitious Plans for 2026 GeneDx's financial performance for 2025 shows significant growth with a 41% increase in revenue. The company outlines ambitious plans for 2026, including new initiatives in pediatric and prenatal diagnostics, while aiming for further revenue growth.
February 23, 2026 GeneDx Holdings Corp. Reports Strong Financial Growth in 2025 GeneDx Holdings Corp. reported a significant 40% increase in revenue for 2025, driven by higher test volumes and strategic acquisitions. While facing operational cost challenges, the company remains optimistic about its future in genomic diagnostics.
February 03, 2026 GeneDx Holdings Corp to Release Fourth Quarter 2025 Financial Results GeneDx Holdings Corp is set to release its highly anticipated Q4 2025 financial results on February 23, 2026. The accompanying conference call will provide stakeholders with insights into the company's performance and future strategies in genomic healthcare.
January 15, 2026 GeneDx Holdings Corp Faces Scrutiny from Halper Sadeh LLC Halper Sadeh LLC is investigating GeneDx Holdings Corp for possible breaches of fiduciary duty by its leadership. The firm encourages shareholders to engage in discussions about their rights and potential remedies, which may include corporate governance reforms and financial incentives.
January 12, 2026 GeneDx Holdings Corp Reports Strong Preliminary 2025 Financial Results and Offers 2026 Guidance GeneDx Holdings Corp. announced strong preliminary financial results for 2025, with revenues reaching $427 million, a 41% increase from the previous year. The company is set for further growth in 2026, projecting revenues of $540 to $555 million, fueled by strategic initiatives in genomic testing aimed at enhancing pediatric care.
January 08, 2026 GeneDx Partners with Komodo Health to Revolutionize Rare Disease Data GeneDx and Komodo Health have partnered to create a comprehensive dataset for rare diseases, merging extensive genomic data with real-world insights. This collaboration aims to improve patient outcomes and accelerate diagnosis and treatment for rare diseases.
January 07, 2026 GeneDx Unveils GenomeDx Prenatal™: A Game Changer in Prenatal Genomic Diagnosis GeneDx has launched GenomeDx Prenatal™, a novel whole genome sequencing test that offers precise insights for pregnancies with fetal anomalies. This test enhances prenatal diagnostics, providing rapid results and comprehensive support for families and clinicians during critical pregnancy moments.
January 06, 2026 GeneDx Appoints Dr. Linda Genen as Chief Medical Officer: A Leap Towards Genomic-First Care GeneDx has appointed Dr. Linda Genen as Chief Medical Officer to strengthen its genomic healthcare initiatives. With extensive experience in clinical practice and innovation, she aims to drive the adoption of genomic medicine, particularly for rare diseases, enhancing patient care and outcomes.
January 05, 2026 GeneDx Sets New Benchmark in Rare Disease Genomics with 2025 Achievements In 2025, GeneDx made significant strides in rare disease genomics, publishing 79 peer-reviewed studies and expanding its GeneDx Infinity™ dataset. Landmark publications and the GUARDIAN study highlight the company's commitment to transforming clinical practices and enhancing patient care through genomic insights.
December 30, 2025 GeneDx to Showcase Innovations at the J.P. Morgan Healthcare Conference 2026 GeneDx Holdings Corp will showcase its genomic innovations at the J.P. Morgan Healthcare Conference 2026, emphasizing its commitment to improving health outcomes. CEO Katherine Stueland's presentation will highlight the company's leadership in rare disease diagnosis and advancements in precision medicine.
December 15, 2025 GeneDx Holdings Corp Celebrates GUARDIAN Study Recognition by JAMA GeneDx's GUARDIAN study was recognized by JAMA for its innovative approach to genomic newborn screening, demonstrating a high parental consent rate and significant diagnostic success. This study is set to reshape pediatric healthcare by facilitating early identification and intervention for serious health conditions in infants.
November 06, 2025 GeneDx Unveils Innovations at NSGC 2025 Annual Meeting GeneDx showcased cutting-edge genomic advancements at the NSGC 2025 Annual Meeting, including its GeneDx Infinity™ platform and sessions on clinical breakthroughs. The company aims to enhance diagnostic accuracy and access to genomic testing for rare diseases.
November 04, 2025 GeneDx Holdings Corp Announces Participation in Key Investor Conferences GeneDx Holdings Corp is set to participate in three major investor conferences, showcasing its advancements in genomic technologies for rare disease diagnosis. The events will include presentations and fireside chats to discuss the company's strategic vision and innovations in healthcare.
October 28, 2025 GeneDx Holdings Corp. Reports Robust Third Quarter 2025 Financial Results GeneDx Holdings Corp. reported significant financial growth in Q3 2025, achieving $116.7 million in revenue, a 52% increase year-over-year. The company continues to enhance its position in genomic medicine, particularly for rare diseases, and has raised its full-year guidance following strong operational performance.
October 28, 2025 GeneDx Holdings Corp: Q3 2025 Financial Report Highlights Robust Growth Amid Challenges GeneDx Holdings Corp's Q3 2025 report highlights a 52% revenue growth driven by increased test volumes, despite ongoing reimbursement challenges and rising operational costs. The company’s strong liquidity and strategic investments in innovation position it well for future growth.
October 24, 2025 GeneDx Holdings Corp Under Scrutiny: Shareholders Encouraged to Explore Their Rights Halper Sadeh LLC is investigating GeneDx Holdings Corp. for possible fiduciary breaches by its management, prompting shareholders to consider their rights. Investors who acquired stock before January 18, 2022, may be eligible for governance reforms and financial remedies.
October 22, 2025 GeneDx Leads the Charge in Genomic Newborn Screening at ICoNS 2025 GeneDx is leading the shift towards genomic newborn screening (gNBS), showcasing its initiatives at the ICoNS 2025. The company emphasizes making genomic insights accessible at birth to drive preventive healthcare and improve outcomes for newborns. With significant studies like GUARDIAN, GeneDx is set to revolutionize standard care practices for newborns globally.
October 14, 2025 GeneDx Strengthens Leadership with Appointment of Dr. Mimi Lee as Chief Precision Medicine Officer GeneDx has appointed Dr. Mimi Lee as Chief Precision Medicine Officer to advance precision medicine initiatives. Her vision aims to shift healthcare towards proactive genomic interventions, enhancing patient outcomes from birth.
October 09, 2025 GeneDx Launches Autism Partnership Program to Enhance Access to Genetic Testing GeneDx has launched its Autism Partnership Program to improve access to genetic testing for autism spectrum disorder. Partnering with Jaguar Gene Therapy, the initiative aims to reduce diagnostic wait times and address barriers faced by families. This groundbreaking program focuses on patients with *SHANK3*-related ASD and offers coverage for genetic testing costs.
October 08, 2025 GeneDx to Present Groundbreaking Research at ASHG Annual Meeting GeneDx Holdings Corp will present significant research at the ASHG Annual Meeting, showcasing advancements in genomic newborn screening, machine learning, and autism studies. Their platform, GeneDx Infinity, offers rich datasets for enhancing diagnostics and unlocking new gene-disease relationships.
October 07, 2025 GeneDx Holdings Corp Set to Announce Third Quarter 2025 Financial Results GeneDx Holdings Corp will announce its Q3 2025 financial results on October 28, followed by a conference call at 8:30 AM ET. Investors can expect insights into the company's performance and future strategies in genomic diagnostics.
October 01, 2025 GeneDx Launches Groundbreaking Genomic Newborn Screening Initiative with NIH Support GeneDx launches the BEACONS initiative, a groundbreaking project integrating genomic sequencing into newborn screening with NIH support. Enrolling up to 30,000 infants, it aims to improve health outcomes by providing early diagnoses of genetic conditions. Ethical considerations and parental involvement are prioritized throughout the initiative.
September 30, 2025 GeneDx Appoints Lisa Gurry as Chief Business Officer to Propel Growth GeneDx has appointed Lisa Gurry as Chief Business Officer to lead its strategic operations and partnerships, focusing on maximizing the GeneDx Infinity database for rare disease diagnosis and drug development. Gurry's extensive background in healthcare and data commercialization positions her well to drive the company's growth and innovation in precision medicine.
September 25, 2025 GeneDx Infinity™: A Game-Changer in Pediatric Genomics GeneDx Infinity™, unveiled at the AAP National Conference, is a groundbreaking dataset enhancing rare disease diagnosis for pediatricians. With 2.5 million genomic patients and diverse data, it empowers clinicians to provide accurate diagnoses and equitable outcomes.
July 29, 2025 GeneDx Holdings Corp Reports Robust Q2 2025 Performance Amidst Challenges GeneDx Holdings Corp showcased a strong Q2 2025 with a 46% revenue increase, primarily driven by a surge in genomic test volumes. Despite facing reimbursement challenges, the company is optimistic about its future growth through strategic investments and the integration of Fabric Genomics.
May 07, 2025 GeneDx Completes Acquisition of Fabric Genomics: A New Era for Genomic Medicine GeneDx has completed its acquisition of Fabric Genomics, aiming to integrate AI-driven genomic interpretations into healthcare. This merger is set to enhance diagnostic capabilities, particularly in neonatal care, and promote global commercial expansion, signaling a transformative shift in genomic medicine.
April 30, 2025 GeneDx Holdings Corp: Q1 2025 Financial Report Highlights Growth and Challenges GeneDx Holdings Corp reported a 40% revenue increase in Q1 2025, driven by higher test volumes and strategic investments. However, reimbursement challenges and rising operational costs present ongoing hurdles for growth.
April 30, 2025 GeneDx Holdings Corp. Reports Strong First Quarter 2025 Financial Results GeneDx Holdings Corp. announced impressive Q1 2025 financial results, reporting a 42% revenue increase and sustained profitability. The company is enhancing its market leadership through strategic acquisitions and innovative product launches in genomic medicine.
April 16, 2025 GeneDx to Acquire Fabric Genomics, Paving the Way for AI-Enhanced Decentralized Testing GeneDx Holdings Corp has announced the acquisition of Fabric Genomics, marking a significant step in decentralized genomic testing. This merger aims to enhance patient care and reduce healthcare costs through AI-driven genomic interpretation, expanding their market reach in NICU testing and genomic newborn screening.
April 08, 2025 GeneDx Holdings Corp Set to Release Q1 2025 Financial Results GeneDx Holdings Corp is set to announce its Q1 2025 financial results on April 30. Following this, a conference call will provide details on their performance and commitment to personalized healthcare through genomic insights.
April 03, 2025 GeneDx Expands Commercial Footprint with New Focus on Inborn Errors of Immunity GeneDx Holdings is expanding its services to include Inborn Errors of Immunity, enhancing genetic testing for nearly 500 immune disorders. This shift to exome and genome sequencing promises improved diagnostic accuracy and personalized treatment options, significantly benefiting patient care.
March 13, 2025 GeneDx to Showcase Key Research and Innovation at ACMG 2025 GeneDx will participate in ACMG 2025, showcasing its AI-powered gene ranker and addressing clinical impacts of RNA sequencing in resolving variants of uncertain significance. The company aims to enhance genomic testing and improve patient outcomes through strategic collaborations and innovative research.
March 13, 2025 GeneDx Unveils AI-Powered Multiscore Tool to Transform Genetic Analysis GeneDx has launched Multiscore, an AI-driven tool aimed at improving genetic analysis by prioritizing relevant genes based on patient data. This innovation enhances diagnostic efficiency and accuracy, significantly reducing turnaround times for results, ultimately benefiting patient care.
March 04, 2025 GeneDx Expands Testing for Cerebral Palsy: A Leap Towards Improved Patient Care GeneDx has expanded its genetic testing services to include cerebral palsy, aiming to improve access to diagnostics for pediatric patients. This initiative highlights the importance of identifying genetic factors associated with CP, potentially leading to personalized treatment strategies and better health outcomes for affected families.
February 24, 2025 GeneDx Holdings Corp: A New Era in NICU Care Through Genomic Testing GeneDx's Seqfirst-neo study marks a pivotal shift in neonatal care by introducing exclusion-based genomic testing in NICUs, significantly increasing genetic diagnoses. This innovative approach addresses disparities in healthcare access, ensuring timely and equitable care for all infants.
February 20, 2025 GeneDx Holdings Corp. Reports Strong Financial Growth in 2024 Annual Report GeneDx Holdings Corp. has reported significant financial growth in 2024, with a 51% increase in revenue reaching $305.5 million. Despite operational challenges, the company's focus on genomic diagnostics positions it well for future success.
February 18, 2025 GeneDx Holdings Corp Reports Impressive Fourth Quarter and Full Year 2024 Financial Results GeneDx Holdings Corp. reported impressive financial results for Q4 and the full year of 2024, showcasing a 64% revenue increase and substantial growth in genomic testing. The company aims for continued expansion in 2025 with ambitious revenue goals and innovative testing solutions.
February 13, 2025 GeneDx Launches ultraRapid Whole Genome Sequencing for NICU and PICU Patients GeneDx has introduced ultraRapid Whole Genome Sequencing, promising actionable genomic results for NICU and PICU patients in just 48 hours. This service aims to significantly improve timely genetic diagnoses, potentially benefiting over 60% of critically ill infants and saving over $15,000 in healthcare costs per child.
February 12, 2025 GeneDx Holdings Corp Set to Showcase Innovations at TD Cowen Health Care Conference GeneDx Holdings Corp will participate in the 45th Annual TD Cowen Health Care Conference, highlighting their innovations in genomic testing. A fireside chat scheduled for March 4 will offer insights into their advancements and commitment to personalized medicine.
February 10, 2025 GeneDx Holdings Corp Expands Access to Genetic Testing Through Epic Integration GeneDx Holdings Corp has partnered with Epic to integrate genetic testing into health systems via the Aura platform. This collaboration aims to streamline diagnostics and enhance patient care by making genetic data more accessible to clinicians, paving the way for improvements in personalized medicine.
January 23, 2025 SWOT Analysis of GeneDx Holdings Corp in 2025 This SWOT analysis of GeneDx Holdings Corp highlights its leadership in genomic diagnostics, focusing on strengths like innovative technology and extensive databases, while addressing weaknesses and external threats. The analysis also identifies opportunities for growth in the evolving healthcare landscape.
October 29, 2024 GeneDx Holdings Corp. Reports Strong Growth in Q3 2024 Financials GeneDx Holdings Corp. reported a 44% increase in revenue for Q3 2024, driven by whole exome and genome testing. Despite a reduced net loss, challenges such as reimbursement and competition loom ahead.
July 30, 2024 GeneDx Holdings Corp. Reports Strong Q2 2024 Results, Highlighting Growth and Strategic Innovations GeneDx Holdings Corp. reported a 45% revenue growth in Q2 2024, reaching $70.5 million, driven by strong demand for genomic services. Despite an adjusted net loss of $23.4 million, the company is well-positioned for future growth with strategic partnerships and innovations.
April 29, 2024 GeneDx Holdings Corp. Reports Strong Q1 2024 Financial Results GeneDx Holdings Corp. has reported a remarkable 45% revenue growth in Q1 2024, driven by a surge in diagnostic test revenue. Despite challenges, the company is strategically positioned for future growth in the genomics sector.

GeneDx Holdings Corp. Reports Strong Growth in Q3 2024 Financials

Last updated: October 29, 2024 •
Taurigo

GeneDx Holdings Corp., a leader in genomic diagnostics specializing in exome and whole genome sequencing, has released its financial results for the third quarter of 2024. The report reveals a remarkable growth trajectory as the company continues to leverage its extensive genomic database and advanced analytical capabilities.

1. Revenue and Profitability

For the three months ended September 30, 2024, GeneDx reported total revenue of $76.9 million, reflecting a substantial 44% increase from $53.3 million in the same period last year. This surge in revenue was primarily attributed to a favorable shift towards higher-margin whole exome and whole genome tests, alongside improved reimbursement rates for these services.

Gross Profit and Margins

The company's gross profit for Q3 2024 reached $47.8 million, a striking increase of 89% compared to $25.3 million in Q3 2023. This growth in gross profit highlights GeneDx's ability to effectively manage costs while increasing test volumes.

Income Statement of GeneDx Holdings Corp
Nov 2023 Oct 2024
Net Income
-458.7M-83.49M
Profit
-458.8M-83.45M
Net Income Continuing
-458.8M-83.45M
Income Tax Expense
-378K-769K
Pretax Income
-459.1M-84.22M
Non-operating Income
20.65M-26.56M
Operating Income
-479.8M-57.66M
Revenue
206.4M267.2M
Other Operating Income
-2.46M-7.38M
Costs and Expenses
683.8M317.5M
Cost of Revenue
163.5M108.2M
Operating Expenses
520.3M209.2M
Impairment Expense
220.5M0
Research & Development
70.38M46.38M
Selling, General & Administrative
224.9M165.6M
Other Operating Expenses
4.39M-2.79M

Despite the encouraging revenue and gross profit figures, GeneDx reported a net loss of $8.31 million for the quarter. This marks an improvement over the net loss of $42.28 million in Q3 2023, indicating a significant reduction in operational losses as the company continues to streamline its operations and enhance its service offerings.

2. Key Performance Indicators

GeneDx focuses on several key performance indicators (KPIs) to evaluate its operations:

  • Number of Resulted Tests: The ongoing increase in test volume is crucial for long-term patient relationships and expanding the genomic database.
  • Mix of Test Results: A strategic emphasis on whole exome and whole genome sequencing has been pivotal in driving profitability.
  • Revenue Growth: The company’s ability to increase revenue by 44% year-over-year underscores its market position and operational effectiveness.

Operating Expenses

Operating expenses totaled $83.88 million for Q3 2024, an increase from $93.47 million in Q3 2023. This decrease in operating expenses as a percentage of revenue reflects the company’s focus on cost management, particularly in research and development and selling, general, and administrative expenses.

3. Balance Sheet Strength

GeneDx’s balance sheet remains robust, with total assets amounting to $408.8 million as of September 30, 2024. This represents a slight decrease from $417.2 million in Q3 2023. The company’s current assets include $186.0 million in cash and equivalents, with a notable portion of $116.4 million held in cash and short-term investments.

Balance Sheet of GeneDx Holdings Corp
Nov 2023 Oct 2024
Total Assets
417.2M408.8M
Total Current Assets
171.8M186.0M
Cash and Equivalents
87.38M57.89M
Short-term Investments
26.9M58.56M
Net Inventories
9.34M10.77M
Accounts Receivable
32.40M38.48M
Prepaid Expenses
15.76M20.3M
Other Current Assets
10K0
Total Non-current Assets
245.4M222.8M
Intangible Assets
176.1M162.1M
Net PP&E
35.74M31.45M
Lease Assets
27.53M24.93M
Other Non-current Assets
6.05M4.33M
Total Liabilities and Equity
417.2M408.8M
Total Liabilities
163.0M204.3M
Total Current Liabilities
68.36M77.34M
Accounts Payable and Accrued Liabilities
38.87M56.41M
Current Debt
3.67M3.69M
Other Current Liabilities
25.81M17.22M
Total Non-current Liabilities
94.66M126.9M
Long-term Debt
6.05M112.4M
Non-current Deferred Tax Liabilities
2.06M1.05M
Other Non-current Liabilities
86.54M13.54M
Total Equity and Non-controlling Interests
254.2M204.5M
Total Equity
254.2M204.5M

Total liabilities stood at $204.3 million, an increase from $163.0 million year-over-year. The increase in liabilities is primarily due to ongoing investments in growth initiatives and the company’s strategic focus on expanding its service offerings.

4. Cash Flow Management

GeneDx reported a net change in cash of $1.81 million for Q3 2024, a significant turnaround compared to a negative cash change of $69.26 million in Q3 2023. The improvement in cash flow can be attributed to better operational efficiencies and a decrease in cash used in operating activities, which amounted to $4.39 million in Q3 2024 versus $41.22 million in the same period last year.

Cash Flow Statement of GeneDx Holdings Corp
Nov 2023 Oct 2024
Net Change in Cash
-117.4M-29.40M
Net Cash from Operating Activities
-214.9M-55.17M
Operating Profit
-458.7M-83.49M
Adjustment to Operating Profit
243.8M28.32M
Net Cash from Investing Activities
-41.7M-34.47M
Business & Interest in Affiliates
12.14M0
Investments
27.27M29.80M
Productive Assets
2.28M4.67M
Net Cash from Financing Activities
139.2M60.24M
Debt
-4.79M45.38M
Equity Issuance/Repurchase
143.9M14.85M

5. Challenges Ahead

Despite the strong financial performance, GeneDx faces several challenges in the evolving genomics landscape:

  1. Reimbursement by Third-Party Payors: The company’s revenue growth heavily relies on its ability to secure reimbursement for its tests from third-party payors.
  1. Intense Competition: The rapidly evolving genomics industry presents continuous competition with frequent introductions of new products and services.
  1. Regulatory Compliance: Adhering to regulatory requirements, particularly in reimbursement and data security, remains a critical focus for the company.

6. Conclusion

GeneDx Holdings Corp. has demonstrated remarkable growth in Q3 2024, achieving substantial increases in revenue and gross profit while reducing net losses. As the company continues to enhance its genomic capabilities and operational efficiencies, it is well-positioned to navigate the challenges of the competitive genomics market. Investors will be keenly watching how GeneDx capitalizes on its strengths to drive future growth and profitability.

Original filing: sec.gov
You may also be interested in:
Products
Resources
Legal
Company
Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.